Cargando…

Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial

BACKGROUND: Preventative measures have recently been taken to reduce the incidence of Alzheimer’s disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the blood–brain barrier, attenuated cognitiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuda, Naoki, Tanaka, Miyuki, Yamauchi, Koji, Abe, Fumiaki, Kakiuchi, Izumi, Kiyosawa, Kyoko, Miyasaka, Mitsunaga, Sakane, Naoki, Nakamura, Masahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266326/
https://www.ncbi.nlm.nih.gov/pubmed/32546992
http://dx.doi.org/10.2147/CIA.S253116
_version_ 1783541286586810368
author Yuda, Naoki
Tanaka, Miyuki
Yamauchi, Koji
Abe, Fumiaki
Kakiuchi, Izumi
Kiyosawa, Kyoko
Miyasaka, Mitsunaga
Sakane, Naoki
Nakamura, Masahiko
author_facet Yuda, Naoki
Tanaka, Miyuki
Yamauchi, Koji
Abe, Fumiaki
Kakiuchi, Izumi
Kiyosawa, Kyoko
Miyasaka, Mitsunaga
Sakane, Naoki
Nakamura, Masahiko
author_sort Yuda, Naoki
collection PubMed
description BACKGROUND: Preventative measures have recently been taken to reduce the incidence of Alzheimer’s disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the blood–brain barrier, attenuated cognitive decline in a mouse model of Alzheimer’s disease. However, the effect of MKP on cognitive function improvement in humans remains unknown. This exploratory study sought to investigate whether MKP intake could improve cognitive function in adults without dementia. METHODS: A total of 268 community-dwelling adults without dementia participated in this 24-week randomized controlled trial. Participants were randomly allocated to the MKP (n = 134) or placebo (n = 134) group. The MKP group received four tablets daily, each containing 50 μg MKP, while the placebo group received four dextrin tablets containing no detectable MKP for 24 weeks. Scores on the Japanese version of the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) were used as the primary outcome to compare cognitive function between the MKP and placebo groups. The study products were also evaluated for safety. RESULTS: The intention-to-treat analysis showed that there was no significant difference between the groups in terms of the ADAS-cog total score. Orientation, as measured by the respective ADAS-cog subscale, was significantly improved compared to placebo at 24 weeks post-MKP administration (P = 0.022). No serious adverse events due to MKP intake were observed. CONCLUSION: To the best of our knowledge, this is the first study to report the effects of MKP on human cognition. These preliminary results suggested the safety of daily MKP intake and its potential to improve orientation in adults without dementia. Further clinical studies are needed to confirm the present findings and the benefits of MKP on cognitive function.
format Online
Article
Text
id pubmed-7266326
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72663262020-06-15 Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial Yuda, Naoki Tanaka, Miyuki Yamauchi, Koji Abe, Fumiaki Kakiuchi, Izumi Kiyosawa, Kyoko Miyasaka, Mitsunaga Sakane, Naoki Nakamura, Masahiko Clin Interv Aging Original Research BACKGROUND: Preventative measures have recently been taken to reduce the incidence of Alzheimer’s disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the blood–brain barrier, attenuated cognitive decline in a mouse model of Alzheimer’s disease. However, the effect of MKP on cognitive function improvement in humans remains unknown. This exploratory study sought to investigate whether MKP intake could improve cognitive function in adults without dementia. METHODS: A total of 268 community-dwelling adults without dementia participated in this 24-week randomized controlled trial. Participants were randomly allocated to the MKP (n = 134) or placebo (n = 134) group. The MKP group received four tablets daily, each containing 50 μg MKP, while the placebo group received four dextrin tablets containing no detectable MKP for 24 weeks. Scores on the Japanese version of the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) were used as the primary outcome to compare cognitive function between the MKP and placebo groups. The study products were also evaluated for safety. RESULTS: The intention-to-treat analysis showed that there was no significant difference between the groups in terms of the ADAS-cog total score. Orientation, as measured by the respective ADAS-cog subscale, was significantly improved compared to placebo at 24 weeks post-MKP administration (P = 0.022). No serious adverse events due to MKP intake were observed. CONCLUSION: To the best of our knowledge, this is the first study to report the effects of MKP on human cognition. These preliminary results suggested the safety of daily MKP intake and its potential to improve orientation in adults without dementia. Further clinical studies are needed to confirm the present findings and the benefits of MKP on cognitive function. Dove 2020-05-27 /pmc/articles/PMC7266326/ /pubmed/32546992 http://dx.doi.org/10.2147/CIA.S253116 Text en © 2020 Yuda et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yuda, Naoki
Tanaka, Miyuki
Yamauchi, Koji
Abe, Fumiaki
Kakiuchi, Izumi
Kiyosawa, Kyoko
Miyasaka, Mitsunaga
Sakane, Naoki
Nakamura, Masahiko
Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial
title Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial
title_full Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial
title_fullStr Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial
title_full_unstemmed Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial
title_short Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial
title_sort effect of the casein-derived peptide met-lys-pro on cognitive function in community-dwelling adults without dementia: a randomized, double-blind, placebo-controlled trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266326/
https://www.ncbi.nlm.nih.gov/pubmed/32546992
http://dx.doi.org/10.2147/CIA.S253116
work_keys_str_mv AT yudanaoki effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial
AT tanakamiyuki effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial
AT yamauchikoji effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial
AT abefumiaki effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial
AT kakiuchiizumi effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial
AT kiyosawakyoko effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial
AT miyasakamitsunaga effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial
AT sakanenaoki effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial
AT nakamuramasahiko effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial